Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04140695 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
A Phase 3 study, sponsored by Vanda Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT04140695 is a Phase 3 study that was terminated before completion, run by Vanda Pharmaceuticals. The registered enrollment target is 87 participants.
The verdict
NCT04140695, a Phase 3 study, was terminated before completion, sponsored by Vanda Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG Tradipitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04140695
The ClinicalTrials.gov registry entry for NCT04140695 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04140695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04140695 about?
NCT04140695 is a clinical study titled "Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
What is the current status of trial NCT04140695?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2019-10-21. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT04140695?
The interventions under investigation include: Placebo (DRUG), Tradipitant (DRUG).
Who is sponsoring clinical trial NCT04140695?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.